SinoVeda and Exzell Pharma Sign Commercialization Agreement for Effecti-Cal®

August 12, 2015

EDMONTON and TORONTO (August 12, 2015): SinoVeda Canada Inc. and Exzell Pharma Inc. today announced the signing of an exclusive license agreement to commercialize Effecti-Cal® in Canada, the U.S., Australia and New Zealand. The agreement includes upfront and milestone payments, as well as royalties on sales. The specific terms of the transaction were not disclosed. […]

Retirement of Paul H. Braconnier

October 23, 2014

SinoVeda Canada today announced the retirement of Paul H. Braconnier from our Board of Directors. Mr. Braconnier has been a valuable member of our team and we wish him well in his active retirement. SinoVeda CFO Al Gourley has been appointed to the Board in his stead.

Positive clinical results for EffectiCal® compared to Caltrate®

May 21, 2014

EDMONTON, Alberta (May 21, 2014 ): SinoVeda Canada Inc. today announces positive clinical results for EffectiCal® from its 24-week double-blind, randomized comparative clinical trial in post-menopausal women.

The results showed that EffectiCal®, a supplement containing 300mg of calcium, was equally as effective as Caltrate® (600mg calcium) and vitamin D3 in measurements of bone formation and bone resorption. Additionally, subjects in this study who received EffectiCal® had significantly fewer gastrointestinal side effects than those taking Caltrate®.